Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma

Leuk Lymphoma. 2004 Oct;45(10):2161-3. doi: 10.1080/10428190410001700803.

Abstract

The incidence of mucormycosis, defined as systemic infection caused by fungi of the class Phycomycetes has been increasing over the past 2 decades, especially in profoundly immunocompromised hosts. We report a new case in a patient presenting with post-transplant high-grade non-Hodgkin's lymphoma who received a prolonged treatment with voriconazole and caspofungin for an invasive pulmonary aspergillosis. Definite diagnosis of mucormycosis was made by liver biopsy of nodules mimicking progressive lymphoma. The patient died 1 week after the diagnosis of mucormycosis despite the administration of liposomal amphotericin B. The role of voriconazole and caspofungin in the emergence of mucormycosis is discussed.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aspergillosis, Allergic Bronchopulmonary / complications*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy
  • Aspergillosis, Allergic Bronchopulmonary / etiology
  • Caspofungin
  • Echinocandins
  • Fatal Outcome
  • Female
  • Humans
  • Kidney Transplantation / adverse effects*
  • Lipopeptides
  • Lymphoma, Non-Hodgkin / complications*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / etiology
  • Middle Aged
  • Mucormycosis / diagnosis
  • Mucormycosis / drug therapy
  • Mucormycosis / etiology*
  • Peptides, Cyclic / adverse effects
  • Pyrimidines / adverse effects
  • Treatment Failure
  • Triazoles / adverse effects
  • Voriconazole

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • Pyrimidines
  • Triazoles
  • Amphotericin B
  • Caspofungin
  • Voriconazole